# Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)

> **NCT04008550** · NA · TERMINATED · sponsor: **University Hospital, Rouen** · enrollment: 101 (actual)

## Conditions studied

- Aortic Valve Stenosis
- Pulmonary Hypertension

## Interventions

- **PROCEDURE:** Right Heart Catheterization

## Key facts

- **NCT ID:** NCT04008550
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-06
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-03-05
- **Target enrollment:** 101 (ACTUAL)
- **Why stopped:** * Delay in enrolment (24% at 1 year)
* Lower than estimated prevalence of PAH (15% instead of 50%)
* Refusal of patients with PAH to participate
- **Last updated:** 2020-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008550, "Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04008550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*